The loss of GLS2 expression during EMT leads to an enhanced glutamine-independent phenotype and decreased mitochondrial activity, while GLS2 restoration in GLS2-negative breast cancer cells exhibits enhanced consumption of mitochondrial glutamine and impairs BCSC-like properties [131]. Here, GLS2 is linked to breast cancer.